WGS
VENTE TOTALE: 3 692 titres (~310 932,12 $ US)
- Insiders
- Stueland Katherine
- Total bought
- —
- Total sold
- $310,932
- Last activity
- 2026-09-09
- Last synced
-
2026-09-12 10:11:06
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-11
WGS presents a mixed picture: while operational improvements and a meaningful genomic sequencing catalyst offer some upside, the combination of a moderate liquidity score (65) and weak fundamental trend score (45)…
The first sentence of the analysis written for WGS on 2026-09-11 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 69.7% | 63.6% | 44.4% | -11.4% | -7.8% | |
| Ebit Margin | -4.4% | -16.2% | -84.0% | -194.9% | -114.3% | |
| Ebitda Margin | 1.5% | -9.1% | -67.4% | -169.7% | -104.0% | |
| Operating Profit Margin | -2.8% | -7.6% | -89.2% | -284.5% | -210.3% | |
| Pretax Profit Margin | -4.9% | -17.2% | -87.2% | -254.8% | -115.6% | |
| Continuous Operations Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Net Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Bottom Line Profit Margin | -4.9% | -17.1% | -86.8% | -233.9% | -115.6% | |
| Current Ratio | 2.463 | 3.611 | 3.100 | 1.474 | 4.774 | |
| Quick Ratio | 2.335 | 3.417 | 2.951 | 1.379 | 4.444 | |
| Solvency Ratio | 0.016 | -0.174 | -0.745 | -1.680 | -1.347 | |
| Cash Ratio | 0.964 | 1.554 | 1.695 | 0.952 | 3.955 | |
| Price To Earnings Ratio | -178.164 | -39.619 | -0.380 | -0.162 | -1.964 | |
| Price To Earnings Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | -0.016 | |
| Forward Price To Earnings Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | -0.016 | |
| Price To Earnings Diluted Ratio | -178.164 | -39.619 | -0.380 | -0.162 | -1.964 | |
| Price To Earnings Diluted Growth Ratio | 2.857 | 0.541 | 0.004 | 0.006 | 0.040 | |
| Price To Book Ratio | 11.349 | 8.428 | 0.293 | 0.351 | 1.242 | |
| Price To Sales Ratio | 8.180 | 6.767 | 0.330 | 0.380 | 2.272 | |
| Price To Free Cash Flow Ratio | 245.230 | -60.813 | -0.360 | -0.267 | -2.282 | |
| Price To Operating Cash Flow Ratio | 105.095 | -72.532 | -0.371 | -0.279 | -2.531 | |
| Debt To Assets Ratio | 0.266 | 0.277 | 0.286 | 0.141 | 0.059 | |
| Debt To Equity Ratio | 0.493 | 0.474 | 0.525 | 0.304 | 0.085 | |
| Debt To Capital Ratio | 0.330 | 0.321 | 0.344 | 0.233 | 0.078 | |
| Long Term Debt To Capital Ratio | 0.220 | 0.175 | 0.188 | 0.024 | 0.028 | |
| Financial Leverage Ratio | 1.850 | 1.710 | 1.837 | 2.149 | 1.428 | |
| Working Capital Turnover Ratio | 2.826 | 2.291 | 2.112 | 1.042 | 0.879 | |
| Operating Cash Flow Ratio | 0.306 | -0.520 | -3.063 | -2.212 | -1.880 | |
| Operating Cash Flow Sales Ratio | 0.078 | -0.093 | -0.889 | -1.360 | -0.897 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.429 | 1.193 | 1.032 | 1.045 | 1.109 | |
| Debt Service Coverage Ratio | 0.587 | -9.004 | -272.704 | -24.801 | -35.297 | |
| Interest Coverage Ratio | -4.648 | -7.656 | 0.000 | -208.186 | -157.372 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.720 | 0.000 | -362.469 | -29.358 | -55.699 | |
| Operating Cash Flow Coverage Ratio | 0.219 | -0.245 | -1.504 | -4.138 | -5.798 | |
| Capital Expenditure Coverage Ratio | 1.750 | -5.190 | -31.544 | -22.284 | -9.162 | |
| Dividend Paid And Capex Coverage Ratio | 1.750 | -5.190 | -31.544 | -22.284 | -9.162 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 534.926 | -75.887 | -0.637 | -0.073 | -0.518 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 69.7% | ▲6.1% | ▲38.0% |
| Ebit Margin | -4.3% | ▲11.9% | ▲78.4% |
| Ebitda Margin | 1.6% | ▲10.6% | ▲71.3% |
| Operating Profit Margin | -2.8% | ▲4.8% | ▲116.1% |
| Pretax Profit Margin | -4.9% | ▲12.3% | ▲91.0% |
| Continuous Operations Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Net Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Bottom Line Profit Margin | -4.9% | ▲12.2% | ▲86.8% |
| Current Ratio | 2.463 | ▼-1.148 | ▼-0.621 |
| Quick Ratio | 2.335 | ▼-1.082 | ▼-0.570 |
| Solvency Ratio | 0.016 | ▲0.190 | ▲0.802 |
| Cash Ratio | 0.964 | ▼-0.590 | ▼-0.860 |
| Price To Earnings Ratio | -178.164 | ▼-138.546 | ▼-134.106 |
| Price To Earnings Growth Ratio | 2.857 | ▲2.315 | ▲2.178 |
| Forward Price To Earnings Growth Ratio | 2.857 | ▲2.315 | ▲2.178 |
| Price To Earnings Diluted Ratio | -178.164 | ▼-138.546 | ▼-134.106 |
| Price To Earnings Diluted Growth Ratio | 2.857 | ▲2.315 | ▲2.167 |
| Price To Book Ratio | 11.349 | ▲2.921 | ▲7.016 |
| Price To Sales Ratio | 8.181 | ▲1.414 | ▲4.595 |
| Price To Free Cash Flow Ratio | 245.230 | ▲306.043 | ▲208.929 |
| Price To Operating Cash Flow Ratio | 105.095 | ▲177.627 | ▲99.219 |
| Debt To Assets Ratio | 0.267 | ▼-0.011 | ▲0.060 |
| Debt To Equity Ratio | 0.493 | ▲0.019 | ▲0.117 |
| Debt To Capital Ratio | 0.330 | ▲0.009 | ▲0.069 |
| Long Term Debt To Capital Ratio | 0.220 | ▲0.045 | ▲0.093 |
| Financial Leverage Ratio | 1.850 | ▲0.140 | ▲0.056 |
| Working Capital Turnover Ratio | 2.826 | ▲0.536 | ▲0.997 |
| Operating Cash Flow Ratio | 0.306 | ▲0.825 | ▲1.779 |
| Operating Cash Flow Sales Ratio | 0.078 | ▲0.171 | ▲0.710 |
| Free Cash Flow Operating Cash Flow Ratio | 0.429 | ▼-0.764 | ▼-0.533 |
| Debt Service Coverage Ratio | 0.587 | ▲9.591 | ▲68.831 |
| Interest Coverage Ratio | -4.648 | ▲3.008 | ▲70.924 |
| Short Term Operating Cash Flow Coverage Ratio | 3.720 | ▲3.720 | ▲92.481 |
| Operating Cash Flow Coverage Ratio | 0.219 | ▲0.464 | ▲2.512 |
| Capital Expenditure Coverage Ratio | 1.750 | ▲6.939 | ▲15.036 |
| Dividend Paid And Capex Coverage Ratio | 1.750 | ▲6.939 | ▲15.036 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 534.926 | ▲610.813 | ▲443.364 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $3.50B | $2.07B | $66.9M | $89.2M | $482.0M | |
| Enterprise value | $3.54B | $2.10B | $86.9M | $28.9M | $114.3M | |
| EV / Sales | 8.29x | 6.87x | 0.43x | 0.12x | 0.54x | |
| EV / Op. cash flow | 106.51x | -73.62x | -0.48x | -0.09x | -0.60x | |
| EV / Free cash flow | 248.52x | -61.72x | -0.47x | -0.09x | -0.54x | |
| EV / EBITDA | 534.93x | -75.89x | -0.64x | -0.07x | -0.52x | |
| Net debt / EBITDA | 7.09x | -1.12x | -0.15x | 0.15x | 1.67x | |
| Current ratio | 2.46x | 3.61x | 3.10x | 1.47x | 4.77x | |
| Income quality | -1.58x | 0.55x | 1.02x | 0.58x | 0.78x | |
| Graham net-net | -$1 | $0 | -$1 | -$11 | $83 | |
| Tax burden | 99.5% | 99.3% | 99.5% | 91.8% | 100.0% | |
| Interest burden | 113.7% | 106.1% | 103.8% | 130.7% | 101.2% | |
| Working capital | $159.4M | $143.2M | $123.5M | $68.3M | $382.3M | |
| Invested capital | $410.5M | $360.3M | $355.5M | $339.3M | $445.0M | |
| Return on assets | -3.7% | -12.5% | -42.0% | -100.7% | -44.3% | |
| Operating ROA | -2.4% | -5.5% | -37.5% | -121.5% | -110.7% | |
| Return on tangible assets | -5.4% | -20.0% | -71.4% | -153.1% | -44.3% | |
| Return on equity | -6.8% | -21.3% | -77.1% | -216.4% | -63.2% | |
| Return on invested capital | -2.5% | -6.3% | -49.3% | -148.8% | -97.8% | |
| Return on capital employed | -2.6% | -6.4% | -50.2% | -166.5% | -98.5% | |
| Earnings yield | -0.6% | -2.5% | -262.9% | -615.7% | -50.9% | |
| Free cash flow yield | 0.4% | -1.6% | -278.0% | -374.0% | -43.8% | |
| Capex / Op. cash flow | 57.1% | -19.3% | -3.2% | -4.5% | -10.9% | |
| Capex / Depreciation | 75.4% | 25.0% | 15.9% | 24.1% | 95.3% | |
| Capex / Sales | 4.4% | 1.8% | 2.8% | 6.1% | 9.8% | |
| SG&A / Sales | 56.0% | 55.2% | 96.1% | 144.1% | 150.2% | |
| R&D / Sales | 16.8% | 15.0% | 28.8% | 36.7% | 49.6% | |
| Stock comp / Sales | 7.5% | 3.0% | -0.2% | 17.9% | 103.4% | |
| Intangibles / Total assets | 31.9% | 37.8% | 41.2% | 34.2% | 0.0% | |
| Days sales outstanding | 63d | 45d | 59d | 67d | 46d | |
| Days payables outstanding | 7d | 26d | 33d | 64d | 71d | |
| Operating cycle | 103d | 80d | 88d | 86d | 99d | |
| Cash conversion cycle | 96d | 54d | 54d | 22d | 28d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+69.2%EV / Sales ▲+20.7%EV / EBITDA ▲+804.9%EV / Op. cash flow ▲+180.124Earnings yield ▲+0.019
Profitability
Return on equity ▲+0.145Return on assets ▲+0.088Return on invested capital ▲+0.038Return on capital employed ▲+0.038Operating ROA ▲+0.032Income quality ▼-2.128Tax burden ▲+0.001
Efficiency
Days sales outstanding ▲+18.526Days payables outstanding ▼-19.199Operating cycle ▲+22.885Cash conversion cycle ▲+42.084Capex / Sales ▲+0.027R&D / Sales ▲+0.019
Balance-sheet strength
Current ratio ▼-1.148Net debt / EBITDA ▲+8.205Working capital ▲+16229000.000Invested capital ▲+50229000.000Intangibles / Total assets ▼-0.059
Change over 5 years
Valuation
Market cap ▲+625.6%EV / Sales ▲+1439.0%EV / EBITDA ▲+103408.4%EV / Op. cash flow ▲+107.106Earnings yield ▲+0.503
Profitability
Return on equity ▲+0.564Return on assets ▲+0.406Return on invested capital ▲+0.953Return on capital employed ▲+0.960Operating ROA ▲+1.084Income quality ▼-2.359Tax burden ▼-0.005
Efficiency
Days sales outstanding ▲+17.800Days payables outstanding ▼-64.355Operating cycle ▲+3.790Cash conversion cycle ▲+68.145Capex / Sales ▼-0.053R&D / Sales ▼-0.327
Balance-sheet strength
Current ratio ▼-2.311Net debt / EBITDA ▲+5.420Working capital ▼-222880000.000Invested capital ▼-34493000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-11 Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation Tempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform
- 2026-09-09 GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
- 2026-09-08 3 Promising Genomics Stocks in the Spotlight in 2026 Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
- 2026-09-01 GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
- 2026-08-26 GeneDx Holdings Corp (WGS) Shares Surge 3.3% -- What GF Score of 65 Tells Investors On August 26, 2026, GeneDx Holdings Corp (WGS) shares rose 3.3%, bringing the current price to $90.28. The stock is trading within a 52-week range of $32.21 to
- 2026-08-26 Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market''s current top-10 short-interest list, per Benzinga Pro data.
- 2026-08-24 GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children''s [url="]GeneDx[/url] (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new data publish
- 2026-08-24 GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children''s GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children''s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
- 2026-08-19 Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates? GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 2026-08-18 GeneDx: Why I Think The Worst Is Behind The Business GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met.